What is the global market size of Amyotrophic Lateral Sclerosis Treatment Market?

Global Amyotrophic Lateral Sclerosis Treatment Market size was valued at USD 647.9 million in 2021 and is poised to grow from USD 685.48 million in 2022 to USD 1138.58 million by 2030, growing at a CAGR of 5.8% in the forecast period (2023-2030).

Amyotrophic Lateral Sclerosis Treatment Companies

Amyotrophic Lateral Sclerosis Treatment Market Competitive Landscape

Top Players in Amyotrophic Lateral Sclerosis Treatment Market

Mitsubishi Tanabe Pharma Corporation
BrainStorm Therapeutics
Biogen Inc.
Sanofi S.A.
Genentech Inc.
Cytokinetics Inc.
Avanir Pharmaceuticals, Inc.
Novartis International AG
Ionis Pharmaceuticals, Inc.
Neuraltus Pharmaceuticals, Inc.
Pfizer Inc.
Anavex Life Sciences Corp.
AB Science
Biohaven Pharmaceutical Holding Company Ltd.
Ono Pharmaceutical Co., Ltd.
Bausch Health Companies Inc.
GW Pharmaceuticals plc
Mitsubishi Chemical Corporation
Regeneron Pharmaceuticals Inc.
Biocytogen, LLC.

Amyotrophic Lateral Sclerosis Treatment Market

FAQs

Global Amyotrophic Lateral Sclerosis Treatment Market size was valued at USD 662.30 million in 2022 and is poised to grow from USD 704.02 million in 2023 to USD 1147.77 million by 2031, growing at a CAGR of 6.3% in the forecast period (2024-2031).

Global amyotrophic lateral sclerosis treatment market is slightly fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some companies are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, and F. Hoffmann-La Roche AG. 'Mitsubishi Tanabe Pharma Corporation', 'BrainStorm Therapeutics', 'Biogen Inc.', 'Sanofi S.A.', 'Genentech Inc.', 'Cytokinetics Inc.', 'Avanir Pharmaceuticals, Inc.', 'Novartis International AG', 'Ionis Pharmaceuticals, Inc.', 'Neuraltus Pharmaceuticals, Inc.', 'Pfizer Inc.', 'Anavex Life Sciences Corp.', 'AB Science', 'Biohaven Pharmaceutical Holding Company Ltd.', 'Ono Pharmaceutical Co., Ltd.', 'Bausch Health Companies Inc.', 'GW Pharmaceuticals plc', 'Mitsubishi Chemical Corporation', 'Regeneron Pharmaceuticals Inc.', 'Biocytogen, LLC.'

Global amyotrophic lateral sclerosis treatment market is projected to be driven by a rise in prevalence of amyotrophic lateral sclerosis disease. According to the Centers for Diseases Control and Prevention (CDC), in 2016, between 14,500 and 15,000 people in the U.S. had amyotrophic lateral sclerosis, of these about 5,000 people are diagnosed annually. Globally, about 2 – 5 people in every 100,000 are affected by ALS. Additionally, inclination toward sedentary lifestyle and increase in the geriatric population fuel the demand for targeted and symptomatic treatment options. This is expected to drive the market during the forecast period.

Due to the hectic schedule of the individual and changing lifestyle there is rising incidences of neurodegenerative disorders which is driving the global amyotrophic lateral sclerosis treatment market. Beside this, expanding geriatric population, who are more susceptible to such neurological ailments, is also augmenting the market growth. Furthermore, several NGO and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted symptomatic treatment options for ALS is acting as a significant growth-inducing factor.

North America had the largest market share in 2018 and is expected to maintain that position throughout the forecast period. The factors driving the market are high healthcare expenditure, favorable reimbursement policies, high demand for ALS drugs, and established healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, approximately 16,583 cases of amyotrophic lateral sclerosis were identified in the United States in 2015.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Growth Analysis, By Treatment(Meditation, Stem Cell Therapy, Others.), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Others (online pharmacies, diagnostics laboratories), By Region - Industry Forecast 2024-2031

Amyotrophic Lateral Sclerosis Treatment Market Competitive Landscape

Amyotrophic Lateral Sclerosis Treatment Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Growth Analysis, By Treatment(Meditation, Stem Cell Therapy, Others.), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Others (online pharmacies, diagnostics laboratories), By Region - Industry Forecast 2024-2031

Amyotrophic Lateral Sclerosis Treatment Market Competitive Landscape

Amyotrophic Lateral Sclerosis Treatment Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Amyotrophic Lateral Sclerosis Treatment Market?

Who are the key vendors in the Amyotrophic Lateral Sclerosis Treatment Market?

What is the key driver of Amyotrophic Lateral Sclerosis Treatment Market?

What is the key market trend for Amyotrophic Lateral Sclerosis Treatment Market?

Which region accounted for the largest share in Amyotrophic Lateral Sclerosis Treatment Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300